Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 11/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337334 | 0.88 | CACNA1B (0.63) | CACNA1BNOTUM | |
| SCHEMBL1336114 | 0.87 | CACNA1B (0.53) | CACNA1BACACBNOTUM | |
| SCHEMBL1336007 | 0.87 | CACNA1B (0.76) | CACNA1BHSD17B10KCNH2ACACBNOTUM | |
| SCHEMBL1337149 | 0.86 | CACNA1B (0.78) | CACNA1BKCNH2 | |
| SCHEMBL1337090 | 0.82 | CACNA1B (0.62) | CACNA1BNOTUM | |
| SCHEMBL1336617 | 0.80 | ACACB (0.46) | CACNA1BACACB | |
| SCHEMBL1337051 | 0.80 | CACNA1B (0.47) | CACNA1BACACBLMNASMN1; SMN2 | |
| SCHEMBL1337441 | 0.80 | CACNA1B (0.65) | CACNA1B | |
| SCHEMBL1337148 | 0.79 | CACNA1B (1.00) | CACNA1BKCNH2 | |
| SCHEMBL16497755 | 0.79 | CACNA1B (0.67) | CACNA1BKCNH2ACACBNOTUMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885HSD17B10 2971/4885KCNH2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.